Global Leading Market Research Publisher QYResearch Announces the Release of Its Latest Report: “Bioprocess Storage Bags – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”
The global biopharmaceutical industry is undergoing a profound transformation driven by single-use technologies, flexible manufacturing systems, and the rising complexity of biologics production. QYResearch’s latest report, “Bioprocess Storage Bags – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”, delivers an in-depth analysis of the current market landscape (2021–2025), forecasts for 2026–2032, and key growth drivers and challenges. This comprehensive study is designed to inform strategic planning, investment decisions, and market expansion strategies for pharmaceutical executives, manufacturing leaders, and investors.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6117131/bioprocess-storage-bags
Market Overview
The global market for bioprocess storage bags was valued at US$ 1,493 million in 2025 and is projected to reach US$ 2,594 million by 2032, reflecting a CAGR of 8.3%. In 2024, total global sales reached approximately 12.87 million units, highlighting the increasing adoption of single-use technologies in biopharmaceutical production.
Bioprocess storage bags play a critical role in the aseptic storage and transfer of liquids such as buffer solutions, culture media, intermediates, and bulk biologics. Their single-use, sterile design helps mitigate contamination risks, improve operational efficiency, and simplify downstream cleaning and validation processes in cell therapy, vaccine production, and recombinant protein manufacturing.
Product Definition and Technical Features
Bioprocess storage bags are typically made from multilayer co-extruded films, such as EVA (ethylene-vinyl acetate), EVOH (ethylene vinyl alcohol), and ULDPE (ultra-low-density polyethylene). After gamma-ray sterilization, these bags offer:
- High chemical compatibility for a wide range of biologics and buffers
- Structural stability under agitation or storage
- Enhanced safety and reproducibility in liquid transfer and storage processes
Manufacturing and cost structure:
- Raw materials (imported multilayer films) account for 35–45% of total selling price
- Cleanroom labor, bag welding, and depreciation represent 15–20%
- Gamma sterilization, quality control, and validation costs account for 10–15%
- The remainder includes gross profit, distribution, and after-sales support
Domestic production of membrane materials can reduce raw material costs by up to 40%, leading to an overall 25–30% reduction in bag cost, which explains why locally produced bags are often 40% cheaper than imports.
Industry Value Chain
The bioprocess storage bag market is shaped by a vertically integrated ecosystem:
1. Upstream:
- Suppliers of multilayer co-extruded films and polymer resins
- Additives to enhance oxygen barrier properties, UV resistance, and mechanical strength
- Specialty coatings for enhanced sterility and chemical compatibility
2. Midstream:
- Manufacturers produce 2D and 3D bag configurations, often under GMP or ISO 13485 compliance
- Operations include cleanroom welding, sterilization, quality validation, and packaging
- Process automation is increasingly employed to minimize human error and contamination risk
3. Downstream:
- Hospitals, research institutes, and biopharmaceutical companies form the primary user base
- Applications span cell therapy, vaccine production, monoclonal antibody (MAB) and recombinant protein manufacturing
- Supporting industries include cold-chain logistics, bioreactor integration, and biobank services
Market Drivers
1. Growth in Biologics and Cell Therapy:
- The expanding cell and gene therapy landscape, combined with the increasing production of monoclonal antibodies and recombinant proteins, has fueled the demand for reliable, single-use storage solutions.
2. Operational Efficiency and Risk Mitigation:
- Bioprocess storage bags eliminate the need for complex cleaning validation, reducing downtime and contamination risk.
- Single-use systems facilitate faster batch changeovers, which is critical for multi-product facilities and contract development and manufacturing organizations (CDMOs).
3. Cost Advantages of Localized Production:
- Domestic film production and bag manufacturing allow local suppliers to offer high-quality, lower-cost alternatives, supporting cost-sensitive markets without compromising regulatory compliance.
4. Regulatory and Quality Alignment:
- High-quality bioprocess storage bags meet FDA, EMA, and ICH guidelines, which is vital for therapeutic production and clinical trials, especially in cell therapy and vaccine manufacturing.
Market Challenges
Despite strong demand, several factors constrain the market:
- High reliance on imported raw materials in certain regions, leading to supply volatility
- Competition from traditional stainless-steel bioprocess systems in large-volume applications
- Regulatory hurdles related to sterility, biocompatibility, and traceability
- Limited bag lifespan under repeated stress, requiring careful operational protocols
Companies that invest in quality validation, traceable manufacturing, and modular designs are better positioned to mitigate these risks.
Market Segmentation
By Type:
- 2D Bags: Flat, low-profile bags optimized for storage and basic liquid transfer
- 3D Bags: Flexible, high-capacity bags suitable for complex bioreactor integration and large-volume storage
By Application:
- Cell Therapy: Single-use bags are integral for stem cell storage, transport, and clinical use
- Vaccine Production: Enables aseptic storage of intermediate formulations and bulk vaccines
- Monoclonal Antibodies and Recombinant Proteins: Facilitates bioreactor feeding, intermediate harvesting, and downstream formulation
- Other Applications: Research-grade storage, diagnostic reagent transport, and ancillary manufacturing uses
Key Players
The global Bioprocess Storage Bags market is led by both established multinational corporations and regional innovators:
- Sartorius
- Merck
- Thermo Fisher Scientific
- Danaher
- Avantor
- Corning
- Entegris
- LePure Biotech
- Saint Gobain
- SATAKE MultiMix
- Zhejiang JYSS Bio-Engineering
- Tofflon
- Duoning Biotech
- ABEC
- AUSTAR Group
Companies are leveraging vertical integration, cost reduction strategies, and regional partnerships to expand market share and enhance profitability.
Future Outlook
The bioprocess storage bag market is expected to maintain sustainable growth through 2032, driven by:
- Continued adoption of single-use bioprocessing systems in global biopharma manufacturing
- Expansion of cell therapy and personalized medicine production
- Innovation in bag design, including improved barrier properties, flexible sizing, and advanced sterilization techniques
- Regional production strategies that reduce dependency on imports and lower overall cost
Investors and industry leaders can leverage these insights to identify market entry opportunities, optimize supply chains, and capture share in high-growth segments such as cell therapy and vaccine manufacturing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
